Among the 60.5% (244/403) who were HIV-positive, the majority were receiving antiretroviral therapy (ART) (91.8% (224/244)) and cotrimoxazole (90.2% (211/234)), with a median CD4 count of 229 cells/μL (IQR: 127 to 397) and median ART duration of 6.6 months (IQR: 5.5 to 25.6) by TB treatment completion. Here, CD4 is linked to tuberculosis.